Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Expert consensus document: A consensus on the medical treatment of acromegaly

Nature Reviews Endocrinology volume 10, pages 243–248 (2014)Cite this article

Subjects

Abstract

In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering biochemical, clinical and tumour volume outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments. This document represents the conclusions of the workshop consensus.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Medical management of patients with acromegaly.

Similar content being viewed by others

References

  1. Melmed, S. et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153, 737–740 (2005).

    Article  CAS  Google Scholar 

  2. Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189–3202 (2009).

    Article  CAS  Google Scholar 

  3. Giustina, A. et al. Current management practices for acromegaly: an international survey. Pituitary 14, 125–133 (2011).

    Article  CAS  Google Scholar 

  4. Melmed, S. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013).

    Article  CAS  Google Scholar 

  5. Melmed, S. et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009).

    Article  CAS  Google Scholar 

  6. Katznelson, L. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update: executive summary. Endocr. Pract. 17, 636–646 (2011).

    Article  Google Scholar 

  7. Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558–2573 (2006).

    Article  CAS  Google Scholar 

  8. Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266–3281 (2008).

    Article  CAS  Google Scholar 

  9. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924–926 (2008).

    Article  Google Scholar 

  10. Holdaway, I. M., Rajasoorya, R. C. & Gamble, G. D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004).

    Article  CAS  Google Scholar 

  11. Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89–95 (2008).

    Article  CAS  Google Scholar 

  12. Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555–559 (2011).

    Article  CAS  Google Scholar 

  13. Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010).

    Article  CAS  Google Scholar 

  14. Carmichael, J. D., Bonert, V. S., Mirocha, J. M. & Melmed, S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 523–527 (2009).

    Article  CAS  Google Scholar 

  15. Melmed, S. et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 4405–4410 (2005).

    Article  CAS  Google Scholar 

  16. Mazziotti, G. & Giustina, A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13, 60–67 (2010).

    Article  CAS  Google Scholar 

  17. Giustina, A. et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7, e36411 (2012).

    Article  CAS  Google Scholar 

  18. Colao, A., Auriemma, R. S., Galdiero, M., Lombardi, G. & Pivonello, R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94, 3746–3756 (2009).

    Article  CAS  Google Scholar 

  19. Colao, A. et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. (Oxf.) 70, 757–768 (2009).

    Article  Google Scholar 

  20. Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S. & Melmed, S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011).

    Article  CAS  Google Scholar 

  21. Davi, M. V. et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159, 533–540 (2008).

    Article  CAS  Google Scholar 

  22. Espinosa-de-los-Monteros, A. L., Gonzalez, B., Vargas, G., Sosa, E. & Mercado, M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14, 231–235 (2011).

    Article  CAS  Google Scholar 

  23. Bonadonna, S. et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20, 1837–1844 (2005).

    Article  Google Scholar 

  24. Salvatori, R. et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 13, 115–122 (2010).

    Article  CAS  Google Scholar 

  25. Yang, L. P. & Keating, G. M. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70, 1745–1769 (2010).

    Article  CAS  Google Scholar 

  26. Toledano, Y. et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 12, 285–293 (2009).

    Article  CAS  Google Scholar 

  27. Schopohl, J. et al. Efficacy and acceptability of lanreotide Autogel®120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes 119, 156–162 (2011).

    Article  CAS  Google Scholar 

  28. Murray, R. D. & Melmed, S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab. 93, 2957–2968 (2008).

    Article  CAS  Google Scholar 

  29. Petersenn, S. et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab. 95, 2781–2789 (2010).

    Article  CAS  Google Scholar 

  30. Tuvia, S. et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97, 2362–2369 (2012).

    Article  CAS  Google Scholar 

  31. Sandret, L., Maison, P. & Chanson, P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011).

    Article  CAS  Google Scholar 

  32. Maione, L. et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714–E1719 (2012).

    Article  CAS  Google Scholar 

  33. van der Lely, A. J. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589–1597 (2012).

    Article  CAS  Google Scholar 

  34. Bonert, V. S. et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J. Clin. Endocrinol. Metab. 93, 3515–3518 (2008).

    Article  CAS  Google Scholar 

  35. Garcia Basavilbaso, N. et al. Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front. Horm. Res. 38, 42–49 (2010).

    Article  CAS  Google Scholar 

  36. Sievers, C. et al. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin. Endocrinol. (Oxf.) 73, 89–94 (2010).

    CAS  Google Scholar 

  37. Trainer, P. J., Ezzat, S., D'Souza, G. A., Layton, G. & Strasburger, C. J. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin. Endocrinol. (Oxf.) 71, 549–557 (2009).

    Article  CAS  Google Scholar 

  38. Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A. & Vandenbroucke, J. P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61–67 (2008).

    Article  CAS  Google Scholar 

  39. Burgers, A. M. et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J. Clin. Endocrinol. Metab. 96, 2912–2920 (2011).

    Article  CAS  Google Scholar 

  40. Colao, A. et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93, 2243–2248 (2008).

    Article  CAS  Google Scholar 

  41. Gouya, H. et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR Am. J. Roentgenol. 190, 1576–1582 (2008).

    Article  Google Scholar 

  42. Annamalai, A. K. et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040–1050 (2013).

    Article  CAS  Google Scholar 

  43. Attal, P. & Chanson, P. Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95, 483–495 (2010).

    Article  CAS  Google Scholar 

  44. Berg, C. et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur. J. Endocrinol. 161, 829–835 (2009).

    Article  CAS  Google Scholar 

  45. Biermasz, N. R. et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur. J. Endocrinol. 166, 407–413 (2012).

    Article  CAS  Google Scholar 

  46. Claessen, K. M. et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 17, 44–52 (2014).

    Article  CAS  Google Scholar 

  47. Mazziotti, G. et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008).

    Article  CAS  Google Scholar 

  48. Battista, C. et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin. Endocrinol. (Oxf.) 70, 378–382 (2009).

    Article  Google Scholar 

  49. Mazziotti, G. et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500–1508 (2009).

    Article  CAS  Google Scholar 

  50. Roset, M. et al. Cost of clinical management of acromegaly in Spain. Clin. Drug Investig. 32, 235–245 (2012).

    Article  Google Scholar 

  51. Sesmilo, G. et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16, 115–121 (2013).

    Article  Google Scholar 

  52. Bex, M. et al. AcroBel—the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007).

    Article  CAS  Google Scholar 

  53. Bevan, J. S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 1856–1863 (2005).

    Article  CAS  Google Scholar 

  54. van der Lely, A. J. et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86, 478–481 (2001).

    Article  CAS  Google Scholar 

  55. Jimenez, C. et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur. J. Endocrinol. 159, 517–523 (2008).

    Article  CAS  Google Scholar 

  56. Buhk, J. H. et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab. 95, 552–558 (2010).

    Article  CAS  Google Scholar 

  57. Marazuela, M. et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J. Clin. Endocrinol. Metab. 96, E251–E259 (2011).

    Article  CAS  Google Scholar 

  58. Carlsen, S. M. et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. (Oxf.) 74, 736–743 (2011).

    Article  CAS  Google Scholar 

  59. Mao, Z. G. et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol. 162, 661–666 (2010).

    Article  CAS  Google Scholar 

  60. Shen, M. et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr. J. 57, 1035–1044 (2010).

    Article  Google Scholar 

  61. Pita-Gutierrez, F. et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS ONE 8, e61523 (2013).

    Article  CAS  Google Scholar 

  62. Trainer, P. J. ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161 (Suppl. 1), S19–S24 (2009).

    Article  CAS  Google Scholar 

  63. Higham, C. E., Chung, T. T., Lawrance, J., Drake, W. M. & Trainer, P. J. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) 71, 86–91 (2009).

    Article  CAS  Google Scholar 

  64. Neggers, S. J. & van der Lely, A. J. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res. 21, 129–133 (2011).

    Article  CAS  Google Scholar 

  65. Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161, 331–338 (2009).

    Article  CAS  Google Scholar 

  66. Mazziotti, G. et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur. J. Endocrinol. 164, 341–347 (2011).

    Article  CAS  Google Scholar 

  67. Fleseriu, M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14, 184–193 (2011).

    Article  CAS  Google Scholar 

  68. Auriemma, R. S. et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur. J. Endocrinol. 162, 993–999 (2010).

    Article  CAS  Google Scholar 

  69. Ozbek, M., Erdogan, M., Akbal, E. & Gonulalan, G. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Exp. Clin. Endocrinol. Diabetes 117, 309–311 (2009).

    Article  CAS  Google Scholar 

  70. Ramirez, C. et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur. J. Endocrinol. 166, 21–26 (2012).

    Article  CAS  Google Scholar 

  71. Ronchi, C. L. et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. J. Endocrinol. 158, 19–25 (2008).

    Article  CAS  Google Scholar 

  72. Colao, A. et al. Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, phase III study. Endocrine Abstr. 29, OC1.1 (2012).

    Google Scholar 

  73. Somm, E. et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Invest. 122, 3295–3306 (2012).

    Article  Google Scholar 

  74. Morin, E., Berthelet, F., Weisnagel, J., Bidlingmaier, M. & Serri, O. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 15, 97–100 (2012).

    Article  CAS  Google Scholar 

  75. Hagen, C., Schroeder, H. D., Hansen, S., Hagen, C. & Andersen, M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur. J. Endocrinol. 161, 631–637 (2009).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank all participants in the Ninth Acromegaly Consensus Group meeting: Michel Aubert (Switzerland), John Ayuk (UK), Ariel Barkan (USA), Albert Beckers (Belgium), Paolo Beck-Peccoz (Italy), Anat Ben Shlomo (USA), Nienke Biermasz (Netherlands), Jens Bollerslev (Norway), Philippe Caron (France), Kazuo Chihara (Japan), Annamaria Colao (Italy), Ettore Degli Uberti (Italy), Eleni Dimarki (USA), William Drake (UK), Diego Ferone (Italy), Maria Fleseriu (USA), Hidenori Fukuoka (Japan), Monica Gadelha (Brazil), Yona Greenman (Israel), Ashley Grossman (UK), Peter Kamenicky (France), Larry Katznelson (USA), Marta Korbonits (UK), Andre Lacroix (Canada), Anton Luger (Austria), Gherardo Mazziotti (Italy), Moises Mercado (Mexico), Sebastian Neggers (Netherlands), Vera Popovic-Brkic (Serbia), Johannes Romijn (Netherlands), Jochen Schopohl (Germany), Gunther Stalla (Germany), Peter Trainer (UK), Jacqueline Trouillas (France), Stylianos Tsagarakis (Greece), Mary Lee Vance (USA), John Wass (UK), Susan Webb (Spain), Margaret Wierman (USA) and Whitney Woodmansee (USA). This study was sponsored by an unrestricted educational grant from Ipsen Ltd, Paris, France. Scientific sponsorship of the meeting was provided by Cedars-Sinai Medical Center. We also acknowledge the editorial assistance provided by Martin Gilmour (ESP Bioscience, Crowthorne, UK), who attended the workshop to take minutes that were used to assist the authors in writing.

Author information

Authors and Affiliations

  1. Chair of Endocrinology, University of Brescia, via Biseo 17, Brescia, 25100, Italy

    Andrea Giustina

  2. Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie et des Maladies de la Reproduction, Hôpitaux Universitaires Paris-Sud, Paris, F 94275, Le Kremlin-Bicêtre, France

    Philippe Chanson

  3. Department of Veterans Affairs Medical Centre, Neuroendocrine Unit, New York University School of Medicine, 423 East 23rd Street, Room 16043W, New York, 10010, NY, USA

    David Kleinberg

  4. Division of Endocrinology and Metabolism, Neuroendocrine Unit, University of São Paulo Medical School, Avenue Dr. Eneas de Carvalho, 255, 7° Andar, Sala 7037, São Paulo, CEP 05403 000, Brazil

    Marcello D. Bronstein

  5. Department of Medicine, University of North Carolina, CB# 7170, 8024 Burnett-Womack, Chapel Hill, NC 27599, USA

    David R. Clemmons

  6. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, 02114, MA, USA

    Anne Klibanski

  7. Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, P.O. Box 2040, Rotterdam, 3000 CA, Netherlands

    Aart J. van der Lely & Steven W. Lamberts

  8. Department of Endocrinology, Charite Campus Mitte, Charitéplatz 1, Berlin, 10117, Germany

    Christian J. Strasburger

  9. Princess Alexandra Hospital, 199 Ipswich Road, Brisbane, 4102, QLD, Australia

    Ken K. Y. Ho

  10. Santiago de Compostela University and CIBERobn, Santiago de Compostela, E-15780, Spain

    Felipe F. Casanueva

  11. Department of Medicine, Cedars-Sinai Medical Center, Room 2015, 8700 Beverly Boulevard, Los Angeles, 90048, CA, USA

    Shlomo Melmed

Authors
  1. Andrea Giustina
    View author publications

    Search author on:PubMed Google Scholar

  2. Philippe Chanson
    View author publications

    Search author on:PubMed Google Scholar

  3. David Kleinberg
    View author publications

    Search author on:PubMed Google Scholar

  4. Marcello D. Bronstein
    View author publications

    Search author on:PubMed Google Scholar

  5. David R. Clemmons
    View author publications

    Search author on:PubMed Google Scholar

  6. Anne Klibanski
    View author publications

    Search author on:PubMed Google Scholar

  7. Aart J. van der Lely
    View author publications

    Search author on:PubMed Google Scholar

  8. Christian J. Strasburger
    View author publications

    Search author on:PubMed Google Scholar

  9. Steven W. Lamberts
    View author publications

    Search author on:PubMed Google Scholar

  10. Ken K. Y. Ho
    View author publications

    Search author on:PubMed Google Scholar

  11. Felipe F. Casanueva
    View author publications

    Search author on:PubMed Google Scholar

  12. Shlomo Melmed
    View author publications

    Search author on:PubMed Google Scholar

Contributions

S.M. and A.G. wrote the majority of the manuscript. All authors made substantial contribution to discussion of content and reviewed/edited the manuscript before submission.

Corresponding author

Correspondence to Shlomo Melmed.

Ethics declarations

Competing interests

A.G. has received consultancy fees from Ipsen, Novartis and Pfizer. P.C. has received consultancy fees and research funding from Ipsen, Novartis and Pfizer. D.K. has received research funding from Novartis, and research funding and consulting fees from Eli Lilly. M.D.B. has received consultancy fees from Chiasma, Ipsen and Novartis, received speaking honoraria from Ipsen and Novartis, and is primary investigator on clinical trials sponsored by Ipsen and Novartis. D.C. has received consultancy fees from Ipsen and Pfizer. A.K. has received research funding from Ipsen and Novartis. A.J.v.d.L. has received research funding and consultancy fees from Ipsen, Novartis and Pfizer. C.S. has received consultancy fees or served as an advisory board member for Chiasma, Pfizer, Novartis, Sandoz and Merck Serono, and received speaker honoraria from Ipsen, Pfizer, Novartis, Novo Nordisk and Eli Lilly. K.K.Y.H. has received consultancy fees from Pfizer and Novartis and speaker honoraria from Novartis and Ipsen. F.F.C. has received fees for advisory board participation from Novartis and research funding from Pfizer. S.M. has received consultancy fees from Chiasma, Novartis, Genentech and Ipsen, and research funding from Pfizer and Novartis. S.W.L. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giustina, A., Chanson, P., Kleinberg, D. et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10, 243–248 (2014). https://doi.org/10.1038/nrendo.2014.21

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2014.21

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing